These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21081945)

  • 21. The increased use of diagnostic procedures in patients with acute myocardial infarction. A community-wide perspective.
    Gore JM; Goldberg RJ; Alpert JS; Dalen JE
    Arch Intern Med; 1987 Oct; 147(10):1729-32. PubMed ID: 3116960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The optimum use of laboratory tests in the surgical patient.
    Rutledge R; Thomas CG; Muakkassa FF; Hansen AR
    N C Med J; 1991 Jan; 52(1):36-40. PubMed ID: 1899918
    [No Abstract]   [Full Text] [Related]  

  • 23. Routine predelivery coagulation screening in previous cesarean patients: impact on patient management.
    Sakala EP; Fillmore K; Murray RD
    J Perinatol; 1989 Dec; 9(4):386-7. PubMed ID: 2512377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening laboratory and radiology panels for trauma patients have low utility and are not cost effective.
    Tasse JL; Janzen ML; Ahmed NA; Chung RS
    J Trauma; 2008 Nov; 65(5):1114-6. PubMed ID: 19001983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Routine admission urinalysis examination in pediatric patients: a poor value.
    Mitchell N; Stapleton FB
    Pediatrics; 1990 Sep; 86(3):345-9. PubMed ID: 2117740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers: from research to utility.
    Bridge-Cook J
    MLO Med Lab Obs; 2011 Jul; 43(7):60. PubMed ID: 21830665
    [No Abstract]   [Full Text] [Related]  

  • 27. Diagnostic testing: the search for real evidence.
    Krau SD
    Crit Care Nurs Clin North Am; 2010 Mar; 22(1):1-6. PubMed ID: 20193875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine.
    Zaric GS
    Pharmacoeconomics; 2016 Jul; 34(7):635-44. PubMed ID: 26899833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incorporating uncertainty into medical decision making: an approach to unexpected test results.
    Bianchi MT; Alexander BM; Cash SS
    Med Decis Making; 2009; 29(1):116-24. PubMed ID: 18812583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Ambulatory co-disciplinary risk-adjusted preoperative care].
    Stöhr G; Weyland W; Post S; Becker H
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():861-3. PubMed ID: 9931740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost implications of selective preoperative risk screening in the care of candidates for peripheral vascular operations.
    Shaw LJ; Hachamovitch R; Cohen M; Berman DS; Borges-Neto S; Udelson JE; Heller GV; Eisenstein EL; Eagle KA; Hendel RC; Miller DD
    Am J Manag Care; 1997 Dec; 3(12):1817-27. PubMed ID: 10178472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What is clinical utility and why should we care?
    Lesko LJ; Zineh I; Huang SM
    Clin Pharmacol Ther; 2010 Dec; 88(6):729-33. PubMed ID: 21081937
    [No Abstract]   [Full Text] [Related]  

  • 33. [Current issues regarding companion diagnostics and future prospects].
    Tazawa Y
    Rinsho Byori; 2014 Apr; 62(4):381-9. PubMed ID: 25022068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding and Improving Diagnostic Tests: The Clinician Perspective.
    Ng PC
    Neonatology; 2019; 115(3):189-196. PubMed ID: 30580336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Making personalized medicine more affordable.
    Aronson N
    Ann N Y Acad Sci; 2015 Jun; 1346(1):81-9. PubMed ID: 25728478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiquated tests within the clinical pathology laboratory.
    Wu AH; Lewandrowski K; Gronowski AM; Grenache DG; Sokoll LJ; Magnani B
    Am J Manag Care; 2010 Sep; 16(9):e220-7. PubMed ID: 21250398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic medicine: a question of value: despite the promise of personalized medicine, genomic testing has yet to prove its cost-effectiveness.
    Nelson B
    Cancer Cytopathol; 2014 Aug; 122(8):557-8. PubMed ID: 25123408
    [No Abstract]   [Full Text] [Related]  

  • 38. Molecular diagnostics clinical utility strategy: a six-part framework.
    Frueh FW; Quinn B
    Expert Rev Mol Diagn; 2014 Sep; 14(7):777-86. PubMed ID: 25109921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of diagnostic tests.
    Laszlo G
    Lancet; 2002 Mar; 359(9311):1065. PubMed ID: 11937207
    [No Abstract]   [Full Text] [Related]  

  • 40. [The drawbacks of diagnostic diligence].
    Stork J
    Ned Tijdschr Geneeskd; 1998 Nov; 142(46):2539-40. PubMed ID: 10028348
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.